International SARS-CoV-2 (COVID-19) Infection Observational Study

Completed

Conditions studied: COVID, COVID19, SARS-CoV 2, Dyspnea

In brief

The general aim of this study is to estimate the rate of disease progression for adults testing positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-CoV-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.

Key facts

Study ID

NCT04385251

Run by

University of Minnesota

People needed

11973

Starts

2020-06-18

Expected to finish

2022-01-31

Last updated by the study team

2022-08-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Not currently hospitalized

You may not qualify if…

• Persons with a known positive SARS-CoV-2 test > 28 days ago

Where it is running

• Denver Public Health — Denver, Colorado, United States
• Hospital General de Agudos JM Ramos Mejia Servicio de Inmunocomprometidos — Buenos Aires, Argentina
• CHIP Department of Infectious Diseases — Copenhagen, Denmark
• University College London Medical School Centre for Sexual Health and HIV Research — London, England, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.